ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.

导出 OA

翻译打印收藏纠错

第一作者： Jiani,Liu

第一单位： Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.

作者： Jiani,Liu ^[1] ; Jiangxue,Wu ^[2] ; Ling,Zhou ^[1] ; Changchuan,Pan ^[1] ; Yi,Zhou ^[3] ; Wuying,Du ^[1] ; Jie-Min,Chen ^[1] ; Xiaofeng,Zhu ^[1] ; Jingnan,Shen ^[1] ; Shuai,Chen ^[4] ; Ran-Yi,Liu ^[1] ; Wenlin,Huang ^[1]

作者单位： Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. ^[1] Department of Oncology, Jingzhou Hospital, Tongji Medical College of Huazhong University of Science and Technology, Jingzhou, Hubei, China. ^[2] Medical Oncology, Sichuan Cancer Hospital and Institute, Second People's Hospital of Sichuan Province, Chengdu, China. ^[3] Musculoskeletal Oncology Department, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. ^[4] Guangdong Provincial Key Laboratory of Tumor Targeted Drugs and Guangzhou Enterprise Key Laboratory of Gene Medicine, Guangzhou Doublle Bioproducts Co. Ltd., Guangzhou, China. ^[5]

关键词 EGFR ZD6474 celecoxib cyclooxygenase-2 osteosarcoma